IGF1R and breast cancer: Subsequent work showed that loss of E-Cadherin increases the sensitivity of breast cancer cells to IGF1R targeted therapy by hyperactivating the IGF1R signaling pathway [26]; nevertheless, neither ACC nor E-cadherin is canonical members of these signaling pathways and the precise mechanisms through which these proteins influence signaling remains hidden.